Plague Pipeline

Oral delivery; strong against injected challenge, weaker on aerosol

A US academic oral vaccine. Attenuated Salmonella Typhimurium carrying F1, the iron receptor Psn, and V. The briefing says protection was strong when the challenge was injected, and weaker when it was an aerosol. The papers span 2004 to 2016. Preclinical. No listed developer is named.

Stage chart

Preclinical

Phase 1

Phase 2

Phase 3

Licensed

Preclinical. Phase 3 is empty here, as it is for every programme in the set.

Years on the record

2004–2016. Labelled “2004–2016” on the briefing. Not a forecast.

Analyst card

Challenge: Oral vaccine. Protection was strong against an injected challenge and weaker against an aerosol.
F1-negative strains: Not reported. Cargo is F1, the iron receptor Psn, and V.
Adjuvant: None named.
Route: Oral.
Stability: Formulation and cold-chain requirement are not stated.
Time to protection: Not reported. No time-to-protection figure is in the briefing.
Other threats: Plague antigens only, inside Salmonella Typhimurium.
Survival figure: No percentage. The briefing only ranks injected protection above aerosol protection.
Animal Rule: Preclinical, 2004–2016. Not an Animal Rule file.

Pipeline record

Vehicle: Attenuated Salmonella Typhimurium.
Cargo: F1, the iron receptor Psn, and V.
Route: Oral.
Result in the briefing: Strong when the challenge was injected. Weaker when it was an aerosol. Papers from 2004 to 2016. US academic. Preclinical.

News

Checking today’s headlines.

Latest intel

Checking Europe PMC.

PubMed

Checking today’s index.

Platform: Bacterial vector
A different bacterium is engineered to carry plague antigens. Several of these are built for an oral dose rather than an injection.
Who is paying: US — academic
Country: United States
What was tested: Injected and aerosol
Stage: Preclinical
Date: 2004–2016
Antigens named: F1V / LcrV